Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 17/20 | 0.71 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.68 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.66 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.66 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17363660 | 1.00 | DNPH1 (0.71) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL16871695 | 1.00 | DNPH1 (0.71) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL17363658 | 0.94 | DNPH1 (0.62) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL17369142 | 0.91 | DNPH1 (0.59) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL17369141 | 0.90 | DNPH1 (0.62) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL17363870 | 0.90 | DNPH1 (0.62) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL16871776 | 0.90 | DNPH1 (0.62) | DNPH1IMPDH2PRKAB2TRPM2LDHA | |
| SCHEMBL1798870 | 0.86 | UBA6 (0.58) | DNPH1TRPM2ADORA1 | |
| SCHEMBL1797855 | 0.86 | UBA6 (0.58) | DNPH1TRPM2ADORA1 | |
| SCHEMBL19699229 | 0.85 | POLB (0.56) | DNPH1IMPDH2P2RY1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | DNPH1 4323/4885IMPDH2 2775/4885PRKAB2 3933/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | DNPH1 2051/4885IMPDH2 1254/4885PRKAB2 4305/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | DNPH1 2035/4885IMPDH2 1249/4885PRKAB2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.